Document is current
Any future updates will be listed below
-
Authors
Costa, Bruno Almeida https://orcid.org/0000-0002-1816-4498
Flynn, Jessica
Nishimura, Noriko
Devlin, Sean M.
Farzana, Tasmin
Rajeeve, Sridevi
Chung, David J. https://orcid.org/0000-0003-0469-839X
Landau, Heather J. https://orcid.org/0000-0002-3152-1189
Lahoud, Oscar B. https://orcid.org/0000-0002-3291-286X
Scordo, Michael
Shah, Gunjan L. https://orcid.org/0000-0002-9977-0456
Hassoun, Hani https://orcid.org/0000-0002-2036-1749
Maclachlan, Kylee https://orcid.org/0000-0001-7873-4854
Hultcrantz, Malin https://orcid.org/0000-0002-9045-6495
Korde, Neha https://orcid.org/0000-0002-5538-4318
Lesokhin, Alexander M. https://orcid.org/0000-0001-9321-702X
Shah, Urvi A. https://orcid.org/0000-0001-8419-1091
Tan, Carlyn R. https://orcid.org/0000-0001-7922-2594
Giralt, Sergio A. https://orcid.org/0000-0003-1944-5053
Usmani, Saad Z. https://orcid.org/0000-0002-5484-8731
Nath, Karthik
Mailankody, Sham https://orcid.org/0000-0002-2815-9561
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
American Society of Hematology (2023 ASH HONORS Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 25 January 2024
Revised: 22 March 2024
Accepted: 28 March 2024
First Online: 27 May 2024
Competing interests
: DJC reports research funding from Genentech. HJL reports research funding from Takeda and consulting fees from Takeda, Genzyme, Janssen, Karyopharm, Pfizer, Celgene, and Caelum Biosciences. OBL reports consulting fees from Incyte and advisory board service for Incyte, Kite, MorphoSys, and Daiichi Sankyo. MS reports consulting fees from McKinsey & Company, Angiocrine Bioscience, and Omeros Corporation; research funding from Angiocrine Bioscience and Omeros Corporation; advisory board service for Kite, a Gilead Company; and honoraria from i3Health and Medscape. GLS reports research funding from Janssen, Amgen, and Beyond Spring. HH reports consulting fees and honoraria from Novartis; research funding from Celgene and Takeda Pharmaceuticals; and advisory board service for Takeda. K.M. reports research funding from ASH, MMRF, and IMS. MH reports research funding from GSK, Amgen, and Daiichi Sankyo; consulting fees from Curio Science LLC, Intellisphere LLC, and BMS; and advisory board service for GSK. NK reports research funding from Amgen and Janssen, and consulting fees from Clinical Care Options, Physician Education Resources, and Cancer Network. AML reports consulting fees from Trillium Therapeutics, Pfizer, Iteos, Sanofi, Genmab, and Janssen; research funding from Pfizer and BMS; royalties from Serametrix; and payment for educational presentations from Janssen and COR2Ed. UAS reports research funding from Celgene/BMS, Janssen, Paula and Rodger Riney Foundation, Allen Foundation, HealthTree Foundation, ASH, and IMS; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH Life Sciences, Intellisphere, Phillips Gilmore Oncology Communications, RedMedEd, and i3Health. CRT reports advisory board fees from Janssen and Sanofi; research funding from Janssen and Takeda; and consulting fees from MJH Life Sciences. SAG reports consulting fees and honoraria from Actinium, Celgene, BMS, Sanofi, Amgen, Pfizer, JAZZ, Janssen, Omeros, GlaxoSmithKline, Takeda, and Kite. SZU reports research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; consulting fees from Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio; and honoraria from Amgen, BMS, Janssen, and Sanofi. SM reports consulting fees from Evicore, Optum, BioAscend, Janssen Oncology, Bristol Myers Squibb, AbbVie, ECor1, Galapagos, and Legend Biotech; honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications; and research funding to MSKCC from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics, and Takeda Oncology. All other authors have no conflicts of interest to disclose.
